Transforming salmonid aquaculture from a consumer to a producer of long chain omega-3 fatty acids

Recommendations to endorse the sustainability of wild fish stock utilisation, supporting the health of marine ecosystems, are clashing with those to increase omega-3 fatty acids (n−3 LC-PUFA) consumption and promoting human health.

The objective of this study was to evaluate the role of salmonid aquaculture as a user or supplier of n−3 LC-PUFA, as a means of understanding the potential of the sector in conserving or depleting wild fisheries. A case-study feeding trial was implemented on rainbow trout up to commercial size, in which fish were fed a fish oil- or a linseed oil-diet. Harvested fish were analysed for fatty acid composition and difference and liking using consumers. The n−3 LC-PUFA input/n−3 LC-PUFA output ratio was computed. Consumers showed no preference, but were able to distinguish between samples. The fatty acids of the fillets were significantly modified by the diets. On the input side, for the production of 100 g of fish fillet, it was necessary to use 8.6 g of n−3 LC-PUFA to produce an output of 1.9 g of n−3 LC-PUFA in the fish oil-fed fish; in contrast it was only necessary to use 270 mg of n−3 LC-PUFA to produce 560 mg of these fatty acids in the linseed oil-fed fish. It was showed that the substitution of fish oil with linseed oil in aquafeed is an easily implemented tool to transform salmonids farming from a consumer into a net producer of health promoting n−3 LC-PUFA and accomplish its role in conserving wild fisheries in the future.

Dietary omega-3 fatty acids and depression in a community sample

To evaluate the association between omega-3 polyunsaturated essential fatty acids and depression, data regarding prevalence rates of self-reported depression and median daily dietary intakes of these fatty acids were obtained from an age-stratified, population-based sample of women (n = 755; 23-97 year) in the Barwon Statistical Division of south-eastern Australia. A self-report questionnaire based on Diagnostic and Statistical Manual-IV criteria was utilised to determine 12-month prevalence rates of depression in this sample, and data from biennial food frequency questionnaires examining seafood and fish oil consumption over a 6-year period were examined. Differences in median dietary intakes of omega-3 fatty acids between the depressed and nondepressed cohorts were analysed and results were adjusted for age, weight and smoking status. No significant differences in median intakes were identified between the two groups of women (median, interquartile range; depressed = 0.09g/day, 0.04-0.18 versus nondepressed = 0.11 g/day, 0.05-0.22, p = 0.3), although overall average intakes of omega-3 fatty acids were lower than recommended and rates of depression within this sample higher than expected, based on previous data. Further research that takes into account ratios of omega-6 to omega-3 polyunsaturated essential fatty acids, as well as other dietary sources of omega-3 fatty acids, is warranted.

Marine nutraceuticals : glucosomine and omega-3 fatty acids : new trends for established ingredients

Glucosamine and long-chain omega-3 lipid are the two most widely consumed marine nutracuticals. These   ingredients have been used as dietary supplement ingredients for many years, but  are now becoming important functional food and beverage ingredients. The production of GRAS and vegetarian glucosamine has led to increased use of this ingredient in beverages in particular. For long chain omega -3 lipid the development of stabilisation technologies has been critical for the increased use of these lipids in functional foods. The development of new sources of both of these ingredients, together with novel delivery and application technologies, will continue to drive increased consumption of these marine nutracuticals, in particular as functional food and beverage ingredients.

Dietary omega-3 fatty acids modify body fluid and cardiovascular homeostasis

Dietary omega-3 fatty acids are important for optimal nutrition. This research demonstrated the significant beneficial effects of these fatty acids on body fluid balance in aging and the regulation of blood pressure. A significant findng was that omega-3 fatty acids reduce neuro-inflammation (inflammation in the brain)

Jumping on the omega-3 bandwagon : distinguishing the role of long-chain and short-chain omega-3 fatty acids

Omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) are almost unanimously recognized for their health benefits, while only limited evidence of any health benefit is currently available specifically for the main precursor of these fatty acids, namely α-linolenic acid (ALA, 18:3n-3). However, both the n-3 LC-PUFA and the short-chain C18 PUFA (i.e., ALA) are commonly referred to as “omega-3” fatty acids, and it is difficult for consumers to recognize this difference. A current gap of many food labelling legislations worldwide allow products containing only ALA and without n-3 LC-PUFA to be marketed as “omega-3 source” and this misleading information can negatively impact the ability of consumers to choose more healthy diets. Within the context of the documented nutritional and health promoting roles of omega-3 fatty acids, we briefly review the different metabolic fates of dietary ALA and n-3 LC-PUFA. We also review food sources rich in n-3 LC-PUFA, some characteristics of LC-PUFA and current industry and regulatory trends. A further objective is to present a case for regulatory bodies to clearly distinguish food products containing only ALA from foods containing n-3 LC-PUFA. Such information, when available, would then avoid misleading information and empower consumers to make a more informed choice in their food purchasing behavior.

Increased hydrolysis by Thermomyces lanuginosus lipase for omega-3 fatty acids in the presence of a protic ionic liquid

We report that the hydrolytic performance of Thermomyces lanuginosus lipase, TLL, and its selectivity towards concentrating clinically important omega 3 fatty acids was increased by the addition of a protic ionic liquid, pIL, Triethylammonium mesylate, TeaMs. We show that TeaMs has a structure altering effect on TLL, changing both the secondary and tertiary structure of TLL. The thermal activity of TLL was also significantly enhanced by the addition of TeaMs.

Oiling the brain : a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan

Around one in four people suffer from mental illness at some stage in their lifetime. There is increasing awareness of the importance of nutrition, particularly omega-3 polyunsaturated fatty acids (n-3 PUFA), for optimal brain development and function. Hence in recent decades, researchers have explored effects of n-3 PUFA on mental health problems over the lifespan, from developmental disorders in childhood, to depression, aggression, and schizophrenia in adulthood, and cognitive decline, dementia and Alzheimer’s disease in late adulthood. This review provides an updated overview of the published and the registered clinical trials that investigate effects of n-3 PUFA supplementation on mental health and behavior, highlighting methodological differences and issues.

Isolation and characterisation of omega-3 fatty acids producing marine microbes

As a renewable alternative to fish oil, microbial-derived omega-3-fatty acids can be potential nutritional supplements. This study reported the isolation of novel oleaginous marine microbes from the Victorian marine environment capable of producing omega-3-fatty acids and other bio-actives. Fermentation strategies using low cost substrates improved omega-3-oils production in selected isolates.

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.

Previous efforts in the prospective evaluation of individuals who experience attenuated psychotic symptoms have attempted to isolate mechanisms underlying the onset of full-threshold psychotic illness. In contrast, there has been little research investigating specific predictors of positive outcomes. In this study, we sought to determine biological and clinical factors associated with treatment response, here indexed by functional improvement in a pre-post examination of a 12-week randomized controlled intervention in individuals at ultra-high risk (UHR) for psychosis. Participants received either long-chain omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) or placebo. To allow the determination of factors specifically relevant to each intervention, and to be able to contrast them, both treatment groups were investigated in parallel. Univariate linear regression analysis indicated that higher levels of erythrocyte membrane α-linolenic acid (ALA; the parent fatty acid of the ω-3 family) and more severe negative symptoms at baseline predicted subsequent functional improvement in the treatment group, whereas less severe positive symptoms and lower functioning at baseline were predictive in the placebo group. A multivariate machine learning analysis, known as Gaussian Process Classification (GPC), confirmed that baseline fatty acids predicted response to treatment in the ω-3 PUFA group with high levels of sensitivity, specificity and accuracy. In addition, GPC revealed that baseline fatty acids were predictive in the placebo group. In conclusion, our investigation indicates that UHR patients with higher levels of ALA may specifically benefit from ω-3 PUFA supplementation. In addition, multivariate machine learning analysis suggests that fatty acids could potentially be used to inform prognostic evaluations and treatment decisions at the level of the individual. Notably, multiple statistical analyses were conducted in a relatively small sample, limiting the conclusions that can be drawn from what we believe to be a first-of-its-kind study. Additional studies with larger samples are therefore needed to evaluate the generalizability of these findings.